公司資料
Merck 股價、新聞與催化劑
- 股票代碼:
- MRK
- 交易所:
- NYSE
- 產業:
- Oncology, Immunotherapy, Vaccines
- 所在地:
- United States
股票表現
135.97 USD (+0.10%)
收盤價
最後更新: 2026年8月17日
286B USD
市值
股價為何變動
As of Aug 17, 2026, MRK was little changed and closed at $135.97. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Merck is a diversified pharmaceutical company with major exposure to oncology, vaccines, infectious disease, and animal health. The company’s market story still revolves around Keytruda, pipeline replacement, and the durability of its broader portfolio.
所在地與產業分類
Headquartered in the United States and listed on NYSE, Merck has a global pharmaceutical footprint with strong international reach. It sits in large-cap biopharma and not in a narrow biotech niche.
商業模式特徵
Merck generates revenue from a mix of blockbuster products, vaccines, and pipeline assets. Investors watch oncology growth, patent lifecycle pressure, vaccine demand, and whether the next wave of products can offset concentration risk.
生技產業定位
Merck is a mature large-cap pharma name with meaningful biotech-like catalyst sensitivity around oncology and vaccine updates. It is less volatile than clinical-stage companies, but major pipeline or label events can still move sentiment.
未來催化劑
- Merck’s next three months are likely to focus on Winrevair uptake, oncology execution, and any pipeline readout that helps replace the market’s dependence on Keytruda. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。